Plasma NfL (pg/mL) | Plasma YKL-40 (ng/mL) | CSF YKL-40 (ng/mL) | |||
---|---|---|---|---|---|
Whole cohort (n = 123) | 18.53 (6.98–216.57) | Whole cohort (n = 125) | 45.1 (8.4–355.1) | Whole cohort (n = 120) | 272.3 (102.4–538.7) |
Controls (n = 39) | 17.03 (6.98–216.57) | Controls (n = 39) | 44.9 (13.0–316.3) | Controls (n = 37) | 307.1 (102.4–506.1) |
MCI-MCI (n = 29) | 17.60 (7.34–45.82) | MCI-MCI (n = 30) | 49.7 (8.4–168.7) | MCI-MCI (n = 28) | 233.6 (126.9–507.2) |
MCI-ADD (n = 27) | 19.57 (7.59–42.38) | MCI-ADD (n = 28) | 44.9 (16.3–248.4) | MCI-ADD (n = 28) | 307.8 (156.2–538.7) |
ADD (n = 28) | 20.81 (12.61–94.97)*, # | ADD (n = 28) | 45.4 (15.8–355.1) | ADD (n = 27) | 260.2 (161.4–519.4) |
p-value | 0.008a | p-value | nsb | p-value | nsc |